menu
    • menu
    [{"orgOrder":0,"company":"Israel Institute for Biological Research","sponsor":"Dyadic International, Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"rVaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Israel Institute for Biological Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Israel Institute for Biological Research \/ Dyadic International","highestDevelopmentStatusID":"1","companyTruncated":"Israel Institute for Biological Research \/ Dyadic International"},{"orgOrder":0,"company":"Israel Institute for Biological Research","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Israel Institute for Biological Research","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Israel Institute for Biological Research \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Israel Institute for Biological Research \/ Not Applicable"},{"orgOrder":0,"company":"Israel Institute for Biological Research","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"Covid-19 vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Israel Institute for Biological Research","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Israel Institute for Biological Research \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Israel Institute for Biological Research \/ Not Applicable"},{"orgOrder":0,"company":"Israel Institute for Biological Research","sponsor":"NRx Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"rVSV-SARS-CoV-2-S Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Israel Institute for Biological Research","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Israel Institute for Biological Research \/ Israel Institute for Biological Research","highestDevelopmentStatusID":"9","companyTruncated":"Israel Institute for Biological Research \/ Israel Institute for Biological Research"},{"orgOrder":0,"company":"Israel Institute for Biological Research","sponsor":"NRx Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"Recombinant Vesicular Stomatitis Virus \u0394G","moa":"SARS-CoV-2 replication","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Israel Institute for Biological Research","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Israel Institute for Biological Research \/ Israel Institute for Biological Research","highestDevelopmentStatusID":"9","companyTruncated":"Israel Institute for Biological Research \/ Israel Institute for Biological Research"},{"orgOrder":0,"company":"Israel Institute for Biological Research","sponsor":"NRx Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"rVSV-SARS-CoV-2-S Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Israel Institute for Biological Research","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Israel Institute for Biological Research \/ NRx Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Israel Institute for Biological Research \/ NRx Pharmaceuticals"},{"orgOrder":0,"company":"Israel Institute for Biological Research","sponsor":"NRx Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"Recombinant Vesicular Stomatitis Virus Delta G","moa":"SARS-CoV-2 replication","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Israel Institute for Biological Research","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Israel Institute for Biological Research \/ Israel Institute for Biological Research","highestDevelopmentStatusID":"9","companyTruncated":"Israel Institute for Biological Research \/ Israel Institute for Biological Research"},{"orgOrder":0,"company":"Israel Institute for Biological Research","sponsor":"Dyadic International, Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Israel Institute for Biological Research","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Israel Institute for Biological Research \/ Israel Institute for Biological Research","highestDevelopmentStatusID":"2","companyTruncated":"Israel Institute for Biological Research \/ Israel Institute for Biological Research"}]

    Find Clinical Drug Pipeline Developments & Deals by Israel Institute for Biological Research

    Menu

    Israel Institute for Biological Research

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Israel Institute for Biological Research

                            Israel arrow
                            PharmaVenue
                            Not Confirmed

                            Israel Institute for Biological Research

                            Israel arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Discovery

                            Recipient : Dyadic International, Inc

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Dyadic Advances Collaboration with IIBR for Bio-Threat Solutions

                            Details : The collaboration supports Dyadic's microbial platforms for protein bioproduction and IIBR’s antibody discovery capabilities to develop innovative solutions for emerging diseases and threats.

                            Brand Name : Undisclosed

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            February 21, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Discovery

                            Recipient : Dyadic International, Inc

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Israel Institute for Biological Research

                            Israel arrow
                            PharmaVenue
                            Not Confirmed

                            Israel Institute for Biological Research

                            Israel arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Recombinant Vesicular Stomatitis Virus Delta G

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II/ Phase III

                            Recipient : NRx Pharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            NRx Reports Remarks by Israel Institute for Biological Research On the Future of The BriLife™ Covid-19 Inves...

                            Details : The BriLife vaccine has unique potential to combat emerging Covid variants and especially to achieve mucosal immunity that has not previously been achieved by mRNA vaccines.

                            Brand Name : BriLife

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            February 11, 2022

                            Lead Product(s) : Recombinant Vesicular Stomatitis Virus Delta G

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II/ Phase III

                            Recipient : NRx Pharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Israel Institute for Biological Research

                            Israel arrow
                            PharmaVenue
                            Not Confirmed

                            Israel Institute for Biological Research

                            Israel arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : rVSV-SARS-CoV-2-S Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I/ Phase II

                            Sponsor : NRx Pharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            NRx Pharmaceuticals and Hungarian Health Officials Agree on Pathway for ZYESAMI® and BriLife COVID-19 Vaccine...

                            Details : IIBR-100 (VSV-ΔG) is a self-propagating live virus vaccine that contains the spike protein of the Wuhan wild-type SARS-CoV-2 virus. Preclinical and phase 1/2 trials have demonstrated no safety signals of concern and have further demonstrated immunologic...

                            Brand Name : IIBR-100

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            December 09, 2021

                            Lead Product(s) : rVSV-SARS-CoV-2-S Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : NRx Pharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Israel Institute for Biological Research

                            Israel arrow
                            PharmaVenue
                            Not Confirmed

                            Israel Institute for Biological Research

                            Israel arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Recombinant Vesicular Stomatitis Virus ΔG

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II/ Phase III

                            Recipient : NRx Pharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            NRx Pharmaceuticals Notes New Data on BriLife® COVID-19 Vaccine Effectiveness Against Delta Variant Posted by...

                            Details : Analysis of Blood Samples from Patients who Responded to the BriLife vaccine During Phase 2 Trial Suggests that the Same Level of Response was Seen Against the Delta Variant as Against the Original “Wild-Type” Virus.

                            Brand Name : BriLife

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            November 26, 2021

                            Lead Product(s) : Recombinant Vesicular Stomatitis Virus ΔG

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II/ Phase III

                            Recipient : NRx Pharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Israel Institute for Biological Research

                            Israel arrow
                            PharmaVenue
                            Not Confirmed

                            Israel Institute for Biological Research

                            Israel arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : rVSV-SARS-CoV-2-S Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II/ Phase III

                            Recipient : NRx Pharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Participants in High Dose BriLife™ Investigational Vaccine Trial for COVID-19 Advised Booster Not Necessary

                            Details : Participants who received lower doses of the BriLife vaccine, rVSV-SARS-CoV-2-S vaccine, have been advised to get a booster vaccination with Pfizer or Moderna shots, as those lower dosages do not appear to offer sufficient long-term protection.

                            Brand Name : IIBR-100

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            August 23, 2021

                            Lead Product(s) : rVSV-SARS-CoV-2-S Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II/ Phase III

                            Recipient : NRx Pharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Israel Institute for Biological Research

                            Israel arrow
                            PharmaVenue
                            Not Confirmed

                            Israel Institute for Biological Research

                            Israel arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Covid-19 vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Israel to Start COVID-19 Vaccine Human Trials on Nov. 1

                            Details : The Israel Institute for Biological Research began animal trials for its “BriLife” vaccine in March. The vaccine, the ministry said, has already tested well on a number of animal models & the IIBR has produced more than 25,000 doses for I & II phases...

                            Brand Name : Undisclosed

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            October 26, 2020

                            Lead Product(s) : Covid-19 vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Israel Institute for Biological Research

                            Israel arrow
                            PharmaVenue
                            Not Confirmed

                            Israel Institute for Biological Research

                            Israel arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : COVID-19 vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Israel tests coronavirus vaccine prototype on rodents at defense lab

                            Details : A source familiar with IIBR activities told Reuters that trials were already under way on rodents. The source declined to identify the kind of rodent.

                            Brand Name : Undisclosed

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            March 31, 2020

                            Lead Product(s) : COVID-19 vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Israel Institute for Biological Research

                            Israel arrow
                            PharmaVenue
                            Not Confirmed

                            Israel Institute for Biological Research

                            Israel arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : rVaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Dyadic International, Inc

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Dyadic and The Israel Institute for Biological Research (IIBR) Expand Collaboration to Combat Emerging Disease...

                            Details : The research collaboration combines IIBR's renowned scientific capabilities and cGMP facilities with Dyadic's patented and proprietary C1 gene expression platform.

                            Brand Name : Undisclosed

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            February 25, 2020

                            Lead Product(s) : rVaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Dyadic International, Inc

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth